David Henley

Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016

Ann McCormack, Olaf M. Dekkers, Stephan Petersenn et al. · European Journal of Endocrinology · 2018 · 269 citations · Full text

A Randomized, Double-Blind Comparison of Olanzapine/Fluoxetine Combination, Olanzapine, and Fluoxetine in Treatment-Resistant Major Depressive Disorder

Michael E. Thase, S. Corya, Olawale Osuntokun et al. · The Journal of Clinical Psychiatry · 2007 · 225 citations

Small Changes in Thyroxine Dosage Do Not Produce Measurable Changes in Hypothyroid Symptoms, Well-Being, or Quality of Life: Results of a Double-Blind, Randomized Clinical Trial

John P. Walsh, Lynley Ward, Valerie Burke et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 163 citations · Full text

Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease

Reisa A. Sperling, David Henley, Paul Aisen et al. · JAMA Neurology · 2021 · 101 citations · Full text

Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study

Gerald Novak, Johannes Streffer, Maarten Timmers et al. · Alzheimer s Research & Therapy · 2020 · 98 citations · Full text